Maternal Serum TSH Value in Early Pregnancy and its Relation with Pregnancy Outcome

Swet Nisha1, Rekha Kumari2, Uday Kumar3

ABSTRACT

Introduction: Thyroid disorders in pregnancy are among the common endocrine disorders. During pregnancy several physiological changes occur in maternal thyroid function and failure to adapt to these changes result in thyroid dysfunction. Thyroid dysfunctions have many adverse effects on mother and fetus, like miscarriages, preeclampsia, eclampsia, placental abruption, preterm delivery, low birth weight, post partum haemorrhage, neonatal hypothyroidism and impaired neurological and intellectual development of fetus. Study aimed to find out the prevalence of thyroid dysfunction in pregnancy and to know maternal and perinatal outcome.

Material and methods: This cross sectional clinical study was carried out at Obstetrics and Gynaecology department in collaboration with Biochemistry Department, IGIMS, Patna, Bihar from August 2018 to August 2019 including 100 pregnant women with single intrauterine pregnancy in first trimester between 6-14th weeks of gestation. TSH level was estimated in all the pregnant women along with FT3, FT4, and Anti TPO Ab. According to the thyroid profile, patients were divided into 4 groups- Normal/ Subclinical/ Overt hypothyroidism and hyperthyroidism and followed till delivery for maternal and perinatal outcome.

Results: In our study of 100 patients, 87 were found to have normal thyroid function and 13 cases were having subclinical hypothyroidism, using a cut off TSH level of 2.5-10uIU/ml in AntiTPO Ab positive and 4-10uIU/ml in AntiTPO Ab negative cases. No case of hyperthyroidism or overt hypothyroidism was found. These 100 patients were divided into two groups. Patients having normal thyroid function were included in Group 1 and patients with subclinical hypothyroidism were included in group 2. In subclinical hypothyroidism group 5(38.46%) cases were AntiTPO Ab positive and 8 cases were AntiTPO Ab negative.

Conclusion: Our study concludes that there is high prevalence of subclinical hypothyroidism (13%) in pregnant women during 1st trimester. No significant difference was seen in maternal and foetal outcome between euthyroid patients and treated subclinical hypothyroid patients.

Keywords: Hypothyroidism, Pre eclampsia, Thyroid Dysfunction

INTRODUCTION

Pregnancy has a profound but reversible effect on the thyroid gland and its function. These physiological changes include increased concentrations of thyroid hormone-binding globulin, thyroid hormones and thyroglobulin, enhanced iodine clearance by the kidneys and a mild thyrotropic effect of rising human chorionic gonadotropin on TSH secretion.1 In developing countries, women living in iodine deficient area do not cope up with the changes, resulting in hypothyroidism during pregnancy. In iodine replete areas, the prevalence of spontaneous hypothyroidism has been found to be 1-2%, and it is more common in older women.2 Hypothyroidism in women causes subfertility and even if they conceive, there is increased risk of abortion, gestational hypertension, abortion plaeneta, preterm labour, anaemia and post-partum haemorrhage.3 Hypothyroidism causes irreversible brain damage of fetus leading to neurological abnormalities, neonatal jaundice, delayed milestone and decreased intelligent quotient level.4,5,6,7 In developed countries, the commonest cause of hypothyroidism in pregnancy is autoimmune thyroiditis.8 Thyroid auto-immunity appears to be a risk factor for abortions and preterm birth.9 In the women of reproductive age group the presence of thyroid antibodies is relatively common.9,10,11 During pregnancy the presence of anti-thyroid peroxidase (anti-TPO) antibodies alerts to the risk of the development of post-partum thyroiditis, reported to be developed in approximately 50% of the women.12,13 The present study was carried out to know the prevalence of thyroid disorders in pregnancy and its maternal and foetal outcome.

MATERIAL AND METHODS

This Longitudinal prospective clinical study was carried out at Obstetrics and Gynaecology department in collaboration with Biochemistry department, IGIMS, Patna, Bihar after clearance from institutional ethics committee. 100 OPD patients visiting obstetrics and gynaecology department of IGIMS, Patna were taken into the study.

Inclusion Criteria

Singleton pregnancy between 6-12 weeks
Primigravida /Multigravida

Exclusion Criteria

Documented history of Thyroid Dysfunction on treatment
Multiple pregnancy

1Senior Resident, Department of Obstetrics and Gynaecology, IGIMS, Patna, 2Additional Professor & HOD, Department of Biochemistry, IGIMS, Patna, 3Professor, Department of Biochemistry, PMCH, Patna, India

How to cite this article: Swet Nisha, Rekha Kumari, Uday Kumar. Maternal serum TSH Value in early pregnancy and its relation with pregnancy outcome. International Journal of Contemporary Medical Research 2020;7(1):A8-A13.

DOI: http://dx.doi.org/10.21276/ijcmr.2020.7.1.15
Gestational Trophoblastic diseases
Any medical co-morbidities
Bad obstetric history

Informed consent was taken from all the patients and along with the routine investigations, TSH, FT3, FT4 and Anti TPO Ab were done in all the patients. The patients were divided into two groups according to TSH levels Group 1 (Euthyroid) and Group 2 (Subclinical hypothyroid). Levothyroxine was supplemented to all the subclinical hypothyroid patients. The patients were followed till delivery for maternal and perinatal outcome. Cord blood TSH were collected at the time of delivery.

| Group 1: (Control group) | TSH levels 0.3-4 uIU/ml with normal FT3 and FT4 and Anti TPO Ab negative (n = 87) |
|-------------------------|-----------------------------------------------------------------------------|
| Group 2: (Test group)   | TSH levels >2.5 uIU/ml and Anti TPO Ab positive OR TSH>4uIU/ml with normal FT3 and FT4 (n = 13) |

The patients with TSH values more than 2.5 uIU/ml and Anti TPO Ab positive or TSH > 4uIU/ml irrespective of Anti TPO Ab were given treatment with levothyroxine as per their TSH levels. All these hypothyroid patients were followed after 1 month of treatment, and then every 3 monthly till delivery for TSH levels, clinical condition and pregnancy outcome. None of the patients were found overt hypothyroid or hyperthyroid.

Baseline data: A detailed information with respect to age, parity, educational status, method of conception, menstrual history, obstetrical history, (abortion or preterm delivery) present pregnancy, medical, surgical, personal and family history of every patient was taken. General physical, systemic and obstetric examination was done. If required, period of gestation was confirmed by ultrasonography (USG). Routine investigations (Hb, ABO Rh, HIV, HBsAg, 75mg GCT, Serum TSH, FT3, FT4, Anti TPO Ab and urine R/E) were done in all the patients. Patients with Serum TSH 0.3-4uIU/ml and Anti TPO Ab negative (0-9.0 IU/ml) were categorised as control group (Group-1) whereas patients with Serum TSH>2.5 uIU/ml and Anti TPO Ab positive(>9.0 IU/ml) or Serum TSH>4-10 uIU/ml irrespective of Anti TPO Ab were categorised as subclinical hypothyroid and supplemented with thyroxin according to Serum TSH value (Group-2). None of the patients were overt hypothyroid (serum TSH>10uIU/ml irrespective of Anti TPO Ab status) or hyperthyroid (serum TSH<2.5th percentile or <0.3 uIU/ml).

Maternal outcomes were assessed in respect to:
Abortion
Pre eclampsia
Anemia
Oligohydramnios
Preterm delivery
PPH

Foetal outcomes were assessed by:
Birth weight
NICU admission
Hyperbilirubinemia

Neonatal hyper/hypothyroidism

**STATISTICAL ANALYSIS**

The data was analysed for mean, proportion. Chi square was calculated for association. The P value <= 0.05 was considered as significant. Analysis was done using EPIDATA analysis software V2.

**RESULTS**

The baseline characteristics of the study population are given in table 1. Majority of patients in both the groups were primigravida (59.77% in Group 1, euthyroid and 53.85% in Group 2, subclinical hypothyroid).

![Maternal Outcome](image1)

![Fetal Outcome](image2)
The reference range for normal TSH was 0.3-2.5 uIU/ml if AntiTPO Ab positive and 0.3-4 uIU/ml in AntiTPO Ab negative patients in all the trimesters. Total 13% patients were found to be subclinical hypothyroid. Mean maternal TSH level was significantly higher in group 2 (subclinical hypothyroid) as compared to group 1 (euthyroid) at booking visit. All these subclinical hypothyroid patients were given treatment with levothyroxine as per their TSH levels. All the patients were followed till delivery with Serum TSH level. The mean TSH level at the time of delivery in group 2 patients was significantly lower as compared to the mean TSH levels in 1st trimester and was comparable to euthyroid patients. Mean TSH levels of both the groups are shown in table 2.

Mean FT3 level in group 1 was 2.24±0.431 pg/ml and in group 2 was 2.42±0.38 pg/ml and the difference was not statistically significant. Mean FT4 level in group 1 was 1.02±0.151 ng/dl and in group 2 was 1.04±0.131 ng/dl and the difference was not statistically significant.

Anti TPO Ab (TPO Ab) testing was done in all the patients. Mean TSH levels of both the groups are shown in table 2. Mean FT3 level in group 1 was 2.24±0.431 pg/ml and in group 2 was 2.42±0.38 pg/ml and the difference was not statistically significant. Mean FT4 level in group 1 was 1.02±0.151 ng/dl and in group 2 was 1.04±0.131 ng/dl and the difference was not statistically significant.

The reference range for normal TSH was 0.3-2.5 uIU/ml if AntiTPO Ab positive and 0.3-4 uIU/ml in AntiTPO Ab negative patients in all the trimesters. Total 13% patients were found to be subclinical hypothyroid. Mean maternal TSH level was significantly higher in group 2 (subclinical hypothyroid) as compared to group 1 (euthyroid) at booking visit. All these subclinical hypothyroid patients were given treatment with levothyroxine as per their TSH levels. All the patients were followed till delivery with Serum TSH level. The mean TSH level at the time of delivery in group 2 patients was significantly lower as compared to the mean TSH levels in 1st trimester and was comparable to euthyroid patients. Mean TSH levels of both the groups are shown in table 2.

Mean FT3 level in group 1 was 2.24±0.431 pg/ml and in group 2 was 2.42±0.38 pg/ml and the difference was not statistically significant. Mean FT4 level in group 1 was 1.02±0.151 ng/dl and in group 2 was 1.04±0.131 ng/dl and the difference was not statistically significant.

Anti TPO Ab (TPO Ab) testing was done in all the patients. Mean TSH levels of both the groups are shown in table 2. Mean FT3 level in group 1 was 2.24±0.431 pg/ml and in group 2 was 2.42±0.38 pg/ml and the difference was not statistically significant. Mean FT4 level in group 1 was 1.02±0.151 ng/dl and in group 2 was 1.04±0.131 ng/dl and the difference was not statistically significant.

Anti TPO Ab (TPO Ab) testing was done in all the patients. The TPO Ab levels less than 9 IU/ml were taken as negative. In group 2, 38.46% patients were Anti TPO Ab positive i.e out of 13 subclinical hypothyroid patients, 5 were Anti TPO Ab positive; three patients had TSH levels between 2.5 and 4 uIU/ml and two patients had TSH levels above 6 uIU/ml. All patients in group 1 were Anti TPO Ab negative. In both the groups, majority of deliveries were vaginal i.e 73.56% in euthyroid group (group 1) and 76.92% in subclinical hypothyroid group (group 2). None of the maternal outcome was found to be statistically significant (p> 0.05). Maternal outcomes of both the groups are shown in table 3 and fig-1. Eleven babies (12.64%) in group 1 and four babies (30.77%) in group 2 had NICU admission. There was no intrauterine death in either of the group. Foetal outcomes were also not statistically significant (p>0.05) between the two groups (Table 4, fig-2). Cord blood TSH values were 3.17±2.1 uIU/ml and 4.47±2.4 uIU/ml in group 1 (euthyroid) and group 2 (subclinical hypothyroid) respectively. Positive correlation was observed between maternal TSH at first trimester and cord blood TSH (r = +0.225, p<0.05). Negative correlation was observed between the TSH levels in first trimester and mean birth weight of neonates (r = -0.037, p<0.05). A negative correlation between cord blood TSH and birth weight of babies (r = -0.16, p<0.05) was observed.

**DISCUSSION**

Foetal and placental growth seems to be affected by thyroid dysfunction in early pregnancy. Mean maternal TSH level was significantly higher in group 2 as compared with group 1 at booking visit. Subclinical hypothyroid patients were given treatment with levothyroxine as per their TSH values.
levels. The mean TSH level at the time of delivery in group 2 (subclinical hypothyroid) patients was significantly lower as compared with the mean TSH levels in 1st trimester and was comparable to euthyroid patients. Springer et al. (2009) reported that in normal pregnant women mean TSH levels in first trimester to be 1.213 uIU/ml excluding those with history of thyroid disease and autoimmunity. Human chorionic gonadotropin has thyrotropic activity and thus its elevated concentration is responsible for lower serum TSH levels, mainly in the first trimester. Springer et al., 2009 have also shown an inverse correlation between TSH and FT4 levels due to the thyrotropic properties of human chorionic gonadotropin. Human chorionic gonadotropin levels increase in the first 10 weeks of pregnancy, and then subsequently decrease leading to a decrease in FT4 and an increase in TSH levels. In addition, there is rise in thyroid-binding globulin levels because of high estrogen levels, thereby increasing total T4 levels.

Antithyroid antibodies may serve as a marker of autoimmune condition that causes risk for foetal death i.e exert a direct adverse effect on the pregnancy. Women with thyroid autoimmunity may be euthyroid and suffer subfertility, and used to develop subclinical or overt hypothyroidism during the first trimester. Anti thyroperoxidase (TPO) antibodies have diagnostic and prognostic significance. In the present study, TPO Ab positivity was found to be 38.46% in subclinical hypothyroid group (Group 2). It was observed that all patients in euthyroid group (Group 1) were thyroid auto-antibody negative. The incidence of TPO positivity in pregnant women was reported to be 19.6% by Stagnaro-Green and Glinnoer (2004) and 11.7% by Negro et al. (2006) & Springer et al. (2009). In different studies, TPO Ab positivity has been found to be associated with higher maternal TSH levels and lower FT4 level, and risk of subclinical hypothyroidism increases by 8 fold and risk of overt hypothyroidism increases by 26 fold. Majority of patients were able to carry their pregnancy to term gestation. Mean gestational age at delivery was 38.65 weeks in Group 1 (euthyroid) and 37.39 weeks in Group 2 (subclinical hypothyroid) in the present study. The result was similar to the studies Allan et al., 2000; Mannisto et al., 2009; Casey et al., 2005; Thyroid autoimmunity is an important risk factor for abortion and preterm birth. In women with subclinical hypothyroidism, preterm deliveries were significantly increased, which accounted for increased admissions to the NICU and respiratory distress syndrome in the offspring compared with the offspring of euthyroid women. Seventy two percent (72%) relative reduction in preterm delivery has been shown in euthyroid women with autoantibodies when given treatment with levothyroxine. In our study, 5.75% pre-term deliveries were found in euthyroid group (Group 1) and 7.69% in subclinical hypothyroid group on levothyroxine supplementation (Group 2). Similar to our study, Sharma et al. 2007 showed that there was no significant difference in preterm deliveries among treated hypothyroid and euthyroid patients. In the present study, the incidence of pre-eclampsia was found to be 6.90% in euthyroid group (Group 1) and 15.38% in subclinical hypothyroid group (Group 2) i.e no significant difference was found in treated hypothyroid and euthyroid pregnant women when compared for development of pre-eclampsia, which is similar to Sharma et al. (2007). In the present study, 3 infants (23.08%) in subclinical hypothyroid group (Group 2) and 10 infants (11.49%) in euthyroid group (Group 1) were LBW whereas five infants (5.75%) in euthyroid group (Group 1) and 1 (7.69%) infant in subclinical hypothyroid group (Group 2) were delivered prematurely. For the maturation of tissues of brain, lungs, skeleton, intestine and heart, as well as for the non-shivering thermogenesis in the neonates, thyroid hormone is essential. Thyroid hormone-dependent tissue maturation occurs in a highly regulated, temporal sequence in which the ontogeny of the hypothalamic pituitary-thyroid axis is tightly linked to the tissue-specific expression of the thyroid hormone receptor and the local maturation of the deiodinase system that generates T3 from T4. An association between overt maternal hypothyroidism and low birth weight has been shown by Sardana et al., 2009. Many studies have shown association of thyroid function and autoimmunity in early pregnancy with adverse pregnancy and birth outcomes. An increased rate of preterm delivery has been seen among women with subclinical hypothyroidism. Cord blood TSH values were 3.17±2.1 uIU/ml and 4.47±2.4 uIU/ml in euthyroid group (group 1) and subclinical hypothyroid group (group 2) respectively. Positive correlation was observed between maternal TSH at first trimester and cord blood TSH (r = +0.225, p<0.05). Similar positive correlation between maternal and cord blood TSH, with r-value of +0.08, p<0.05 have been shown by Medici et al. (2011). The association was found to be similar even after exclusion of TPO Ab positive patients and additional correction of ethnicity, smoking and socioeconomic status. It has been shown that pregnant women with inadequate dietary iodine intake in the third trimester had lower birth weight infants than the pregnant women with adequate dietary iodine intake. In the present study, negative correlation was observed between the TSH levels in first trimester and mean birth weight of neonates (r = -0.037, p<0.05). A negative correlation between cord blood TSH and birth weight of babies (r = -0.16, p<0.05) was also observed.

Abalowich et al. (2002) concluded that the outcome of pregnancies was based mainly on the treatment received in both overt or subclinical hypothyroidism. Sharma et al. in 2007 showed that there was no significant difference in the complications between euthyroid patients and hypothyroid patients under treatment. Negro et al. (2006) showed that levothyroxine (LT4) administration in thyroid autoimmunity positive pregnant women, during the early stages of pregnancy, reduces the risk of abortions and the rate of premature deliveries. A recent meta-analysis of 18 cohort studies found that pregnant women with untreated subclinical hypothyroidism are at higher risk for pregnancy loss, placental abruption, premature rupture of membranes, and neonatal death compared with euthyroid women. Current guidelines recommend levothyroxine treatment in...
CONCLUSION

Thyroid profile is a must at first booking visit as fetus needs thyroxine for brain development, growth and lung maturation.

In our study, subclinical hypothyroidism in pregnancy has been found to be the commonest thyroid dysfunction. TSH levels were found to be higher in first trimester in subclinical hypothyroid women as compared to euthyroid pregnant women. Thus, adequate replacement therapy should be done to keep TSH within the specific reference range (ATA). Normal thyroid function is necessary to avoid abortions, to maintain normal placental development and function throughout gestation to avoid preterm deliveries and for proper foetal neurodevelopment. Thus, in the present study, it has been shown that in pregnancy, subclinical hypothyroidism is the commonest thyroid disorder and optimum thyroxine replacement in time results in maternal and perinatal outcome similar to euthyroid patients.

REFERENCES

1. Glinoer D, De Nayer P, Bourdoux P, Lemone M and Robyn C et al. Regulation of maternal thyroid during pregnancy. J. Clin. Endocrinol. Metab. 1990; 71: 276-287.
2. Vanderpump MPJ, Braverman LE, Utiger RD. The epidemiology of thyroid diseases. Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Text, edn Philadelphia JB Lippincott- Raven. 2005; 9: 398-496.
3. Abalovich, M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A and Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002; 12: 63-68.
4. Fantz, C.R, Dagogo J S, Ladenson J H and Gronowski A M. Thyroid function during pregnancy. Clin. Chem. 1999; 45: 2250-2258.
5. Walker J.A., Illions E H, Huddleston J F and Smallridge R C. Racial comparisons of thyroid function and autoimmunity during pregnancy and the postpartum period. Obstet. Gynecol. 2005;106:1365-1371.
6. Haddow, J.E, Palomaki G E, Allan W C, Williams J R and Knight G J et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. New Engl. J. Med. 1999;341: 549-555.
7. Smallridge, R.C. and Ladenson P W. Hypothyroidism in pregnancy: Consequences to neonatal health. J. Clin. Endocrinol. Endocrinol. Metab. 2001;86:2349-2353.
8. Klein R.Z, Haddow J E, Falx J D, Brown R S, Hermos R J, Pulkkinnen A and Mitchell M L. Prevalence of thyroid deficiency in pregnant women. J Clin. Endocrinol. 1991; 35: 41-46.
9. Thangaratinan, S, Tan A, Knox E, Kilby M D, Franklyn J and Comorarasamy A. Association between thyroid autoantibodies and miscarriage and preterm birth: Meta-analysis of evidence. Br. Med. J.2011; 342:10.1136/ bmj.d2616.
10. Stagnaro G A and Glinoer D. Thyroid autoimmunity and the risk of miscarriage. Best Pract. Res. Clin. Endocrinol. Metab.2004;18:167-181.
11. Bussen, S. and Steck T. Thyroid autoantibodies in euthyroid non-pregnant women with recurrent spontaneous abortions. Human Reprod. 1995;10: 2938-2940.
12. Premawardhana L.D.K.E., Parkes A B, John R, Harris B and Lazarus J H. Thyroid peroxidase antibodies in early pregnancy: Utility for prediction of postpartum thyroid dysfunction and implications for screening. Thyroid. 2004;14: 610-615.
13. Nicholson W.K., Robinson K A, Smallridge R C, Ladenson P W and Powe N R. Prevalence of postpartum thyroid dysfunction: A quantitative review. Thyroid, 2006;16: 573-582.
14. Biondi B. Cardiovascular effects of mild hypothyroidism. Thyroid, 2007;17: 625-630.
15. Alexander EK, Pearce EN, Brent GA, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017;27:315-89.
16. Springer D, Zima T and Limanova Z. Reference intervals in evaluation of maternal thyroid function during the first trimester of pregnancy. Eur. J. Endocrinol.,2009; 160: 791-797.
17. Alexander E.K. Autoimmunity: Thyroid autoantibodies and pregnancy risk. Nat. Rev. Endocrinol., 2011;7: 501-502.
18. Negro R., Formoso G, Mangieri T, Pezzarossa A, Dazzi D and Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: Effects on obstetrical complications. J. Clin. Endocrinol. Metab.,2006; 91: 2587-2591.
19. Idris I, Srinivasan R, Simm A and Page R C. Maternal hypothyroidism in early and late gestation: Effect on neonatal and obstetric outcome. J Clin Endocrinol, 2005;63: 5605-5605.
20. Ashoor G., Kametas N A, Akolekar R, Giusado J and Nicolaides K H. Maternal thyroid function at 11-13 weeks of gestation. Fetal Diagn. Ther.,2010; 27: 156-163.
21. Benhadi, N., Wiersinga W M, Reitsma J B, Vrijkotte T G M and Bonsel G J. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur. J. Endocrinol., 2009;160: 985-991.
22. Mannisto T., Vaarasmaki M, Pouta A, Hartikainen A L and Ruokonen A et al. Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: A prospective population-based cohort study. J. Clin. Endocrinol. Metab.,2009; 94: 772-779.
23. Medici, M., de Rijke Y B, Peeters R P, Visser W and de Muinck Keizer-Schrama S M P F et al. Maternal early pregnancy and newborn thyroid hormone parameters: The generation R study. J. Clin. Endocrinol. Metab.,2011; 97: 646-652.
24. Allan W.C., Haddow J E, Palomaki G E, Williams J R and Mitchell M L et al. Maternal thyroid deficiency and pregnancy complications: Implications for population screening. J. Med. Screen, 2000;7: 127-130.
25. Casey B.M., Dashe J S, Wells C E, McIntire D D, Byrd W, Leveno K J and Cunningham F G. Subclinical
hypothyroidism and pregnancy outcomes. Obstet. Gynecol., 2005;105: 239-245.
26. Sharma P.P., Mukhopadhyay P, Mukhopadhyay A, Muraleedharan P D and Begum N. Hypothyroidism in pregnancy. J.Obstet.Gynaecol.India, 2007;57:331-334.
27. Sardana, D., Nanda S and Kharb S. Thyroid hormones in pregnancy and preeclampsia. J. Turk. German Gynaecol. Assoc.,2009; 10: 168-171.
28. Karakosta P, Alegakis D, Georgiou V, Roumeliotaki T and Fthenou E et al. Thyroid dysfunction and autoantibodies in early pregnancy are associated with increased risk of gestational diabetes and adverse birth outcomes. J. Clin. Endocrinol. Metab., 2012; 97: 4464-4472.
29. Alvarez-Pedrerol M., Guxens M, Mendez M, Canet Y and Martorell R et al. Iodine levels and thyroid hormones in healthy pregnant women and birth weight of their offspring. Eur. J. Endocrinol., 2009;160: 423-429.
30. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2543-65.
31. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J 2014;3:76-94
32. Maraka S, Ospina NM, O’Keeffe DT, et al. Subclinical hypothyroidism in pregnancy: a systematic review and meta-analysis. Thyroid 2016;26:580-90.

Source of Support: Nil; Conflict of Interest: None
Submitted: 13-12-2019; Accepted: 31-12-2019; Published: 23-01-2020